Top 10 Companies in the Global Pharmaceutical Grade Sodium Carboxymethyl Cellulose (CMC) Market (2026): Market Leaders Powering Global Pharmaceutical Excipients

MARKET INSIGHTS

The Global Pharmaceutical Grade Sodium Carboxymethyl Cellulose (CMC) Market was valued at USD 372.5 million in 2024. The market is projected to grow from USD 390.8 million in 2025 to USD 576.3 million by 2032, exhibiting a CAGR of 5.8% during the forecast period.

Pharmaceutical Grade Sodium Carboxymethyl Cellulose (CMC) is a high‑purity, water‑soluble polymer derived from cellulose. It functions as a versatile excipient in drug formulations, acting as a binder, disintegrant, suspending agent, and stabilizer to control the release and stability of active pharmaceutical ingredients (APIs). Its non‑toxic, hypoallergenic, and high viscosity properties make it essential for producing tablets, gels, creams, and oral liquid medications.

The market is experiencing steady growth driven by the expanding pharmaceutical industry, increased production of generic drugs, and the growing demand for novel drug delivery systems. While the oral solid dosage form segment remains a dominant application area, the rise in biologics and topical formulations is creating new demand. Recent strategic moves by key players, such as capacity expansions and product purity enhancements, are strengthening the supply chain to meet stringent pharmacopeial standards from USP, EP, and JP. Major market participants include Ashland, Nouryon, and SINOCMC, who maintain a competitive edge through extensive product portfolios and compliance with Good Manufacturing Practices (GMP).

Global Pharmaceutical Grade Sodium Carboxymethyl Cellulose (CMC) Market – View in Detailed Research Report

Top 10 Companies in the Global Pharmaceutical Grade Sodium Carboxymethyl Cellulose (CMC) Market (2026)

1. Ashland

Headquarters: Cranberry Township, Pennsylvania, USA

Key Offering: Pharmaceutical‑grade CMC for tablet binders, disintegrants, and suspending agents.

Ashland’s CMC portfolio is known for ultra‑high purity and robust rheological performance, enabling its use in both conventional oral solid dosage forms and emerging controlled‑release technologies. The company’s global R&D network continuously refines particle size distribution and functionalization to meet evolving API requirements.

Sustainability & Growth Initiatives:

• Investment in advanced purification technologies to achieve >99.5% purity.
• Expansion of manufacturing capacity in Asia to meet rising regional demand.
• Collaboration with pharmaceutical OEMs to develop sustainable excipient solutions.

2. Nouryon

Headquarters: Zwijndrecht, Netherlands

Key Offering: High‑purity CMC for tablet coating, suspensions, and topical formulations.

Nouryon’s CMC products are engineered for optimal viscosity control and low heavy‑metal content, aligning with USP, EP, and JP standards. The company’s global supply chain emphasizes traceability and consistent quality across all grades.

Sustainability & Growth Initiatives:

• Implementation of a circular raw‑material sourcing program.
• Carbon‑neutral production goal by 2035.
• Strategic partnerships with contract manufacturers to accelerate product innovation.

3. CP Kelco

Headquarters: Zeeland, Netherlands

Key Offering: Pharmaceutical‑grade CMC for binders, disintegrants, and suspending agents.

CP Kelco’s CMC is distinguished by its consistent particle size distribution and low impurity profile, making it suitable for both oral solid and liquid dosage forms. The company’s research division focuses on enhancing functional properties for complex drug delivery systems.

Sustainability & Growth Initiatives:

• Investment in renewable energy for manufacturing facilities.
• Development of biodegradable excipient formulations.
• Expansion of capacity in emerging markets such as India and Brazil.

4. Mingtai Chemical Co., Ltd.

Headquarters: Nanjing, China

Key Offering: Pharmaceutical‑grade CMC for tablet binders and suspensions.

Mingtai’s CMC is produced using a patented purification process that delivers high purity and low heavy‑metal content. The company serves a large domestic market and has recently expanded its export footprint to Southeast Asia.

Sustainability & Growth Initiatives:

• Implementation of a zero‑waste manufacturing protocol.
• Collaboration with local universities for advanced polymer research.
• Expansion of production lines to meet projected 2028 demand.

5. SINOCMC

Headquarters: Shanghai, China

Key Offering: Ultra‑high purity CMC for injectable drugs and ophthalmic solutions.

SINOCMC’s CMC is tailored for parenteral applications, featuring stringent purity thresholds and robust sterility profiles. The company’s R&D team focuses on functionalizing CMC for improved bioavailability.

Sustainability & Growth Initiatives:

• Investment in advanced filtration technologies.
• Carbon‑footprint reduction program targeting 30% lower emissions by 2030.
• Partnerships with global pharma firms for joint product development.

6. Daicel Miraizu Ltd.

Headquarters: Tokyo, Japan

Key Offering: Pharmaceutical‑grade CMC for tablet binders and controlled‑release systems.

Daicel Miraizu’s CMC offers high viscosity and excellent binding strength, supporting the manufacture of complex dosage forms. The company maintains a strong presence in the Asia‑Pacific market.

Sustainability & Growth Initiatives:

• Adoption of green chemistry principles in synthesis.
• Development of low‑energy purification processes.
• Expansion of production capacity in China to meet regional demand.

7. DKS Co. Ltd.

Headquarters: Osaka, Japan

Key Offering: Pharmaceutical‑grade CMC for suspending agents and tablet binders.

DKS’s CMC is engineered for consistent rheology and low impurity levels, enabling its use in both oral and topical formulations. The company’s R&D focuses on enhancing functional properties for novel drug delivery platforms.

Sustainability & Growth Initiatives:

• Implementation of water‑recycling systems in production.
• Development of biodegradable excipient blends.
• Strategic expansion into emerging markets such as Vietnam.

8. Hansstar Chemical Co., Ltd.

Headquarters: Tianjin, China

Key Offering: Pharmaceutical‑grade CMC for tablet binders and suspensions.

Hansstar’s CMC delivers high purity and robust performance across a range of dosage forms. The company’s manufacturing facilities incorporate advanced quality control systems to ensure compliance with global pharmacopeial standards.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources for production.
• Implementation of a closed‑loop water system.
• Expansion of production lines to support 2026 demand forecasts.

9. Shandong Head Co., Ltd.

Headquarters: Qingdao, China

Key Offering: Pharmaceutical‑grade CMC for tablet binders and coating agents.

Shandong Head’s CMC is recognized for its high viscosity and low impurity profile, supporting the manufacture of high‑quality tablets and coated dosage forms.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient production lines.
• Partnership with local universities for advanced polymer research.
• Expansion of capacity to meet projected 2027 demand.

10. Zibo Hailan Chemical Co., Ltd.

Headquarters: Zibo, China

Key Offering: Pharmaceutical‑grade CMC for tablet binders and suspending agents.

Zibo Hailan’s CMC offers excellent binding performance and consistent rheological properties, making it suitable for a wide range of oral solid dosage forms.

Sustainability & Growth Initiatives:

• Implementation of a carbon‑neutral production goal by 2035.
• Adoption of green chemistry processes in synthesis.
• Expansion of production capacity to support 2026 market growth.

Global Pharmaceutical Grade Sodium Carboxymethyl Cellulose (CMC) Market – View in Detailed Research Report

Global Pharmaceutical Grade Sodium Carboxymethyl Cellulose (CMC) Market – View in Detailed Research Report

Outlook: The Future of Pharmaceutical Grade Sodium Carboxymethyl Cellulose (CMC) Market

The Global Pharmaceutical Grade Sodium Carboxymethyl Cellulose (CMC) Market is poised for steady expansion, driven by the continued growth of the pharmaceutical industry and the increasing demand for high‑purity excipients in innovative drug delivery systems. The market is projected to reach USD 600 million by 2034, reflecting sustained investment in R&D and capacity expansion by key players.

Key Trends Shaping the Market

• Shift towards multi‑functional excipients that combine binding, suspending, and coating capabilities within a single formulation.
• Growing adoption of high‑purity grades (>99.5%) to meet stringent regulatory requirements for parenteral and ophthalmic applications.
• Expansion of production capacity in emerging economies, particularly in Asia‑Pacific, to support local pharmaceutical manufacturing.
• Increasing focus on sustainability, including renewable energy use, carbon‑neutral production goals, and circular raw‑material sourcing.
• Rising demand for controlled‑release and advanced drug delivery platforms that rely on the rheological versatility of CMC.